Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

benjamin craigAbstract: This presentation will briefly cover three topics.

First, it will introduce the history and breadth of health preference research. Apart from its scientific discoveries, the relevance of preference evidence derives from its applications in medical product development, health policy and clinical practice as well as helping individual patients faced with preference-sensitive decisions.Second, we will examine the design of discrete choice experiments for health valuation, including recent innovations in the calculation of QALY estimates for adult and child health outcomes.Third, the presentation will introduce ongoing initiatives within the International Academy of Health Preference Research (iahpr.org), including its textbook (with Oxford University Press), its journal (The Patient), the Health Preference Study and Technology Registry (hpstr.org), and its 10th Meeting in Basel, 13-14 July 2019 (directly prior to iHEA). 

The presentation will conclude with a few thoughts on what to expect in the coming years, such as the integration of patient preferences into economic evaluations and its methodological limitations.

Biography: Benjamin M. Craig, PhD, is an Associate Professor of Economics at the University of South Florida. He received his MS in Economics at the University of Texas at Austin in 1999 and his PhD in Population Health from the University of Wisconsin in 2003. Trained as an econometrician, his research focuses on health preference research and the economics of cancer prevention, detection, and control. He is first author on 7 of the 8 US health valuation studies currently available (PROMIS-29, EQ-5D-5L, SF-6D, PRO-CTCAE, EQ-5D-Y, BPI, NS-CSHCN, not EQ-5D-3L). He is an active member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the International Society for Quality of Life Research (ISOQOL), the International Academy of Health Preference Research (IAHPR), and the EuroQol Group.